Track topics on Twitter Track topics that are important to you
Filing of the 2016 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report
Paris, France - March 3, 2017 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document de Référence" containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
These documents are available on the "Investors" page of the company's corporate website (www.sanofi.com), under the heading "Regulated Information in France". In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document de Référence" is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
| Media Relations|
Tel: + (33) 1 53 77 46 46
| Investor Relations|
Tel.: + (33) 1 53 77 45 45
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...